"Famotidine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Descriptor ID |
D015738
|
| MeSH Number(s) |
D02.886.675.215 D03.383.129.708.215
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Famotidine".
Below are MeSH descriptors whose meaning is more specific than "Famotidine".
This graph shows the total number of publications written about "Famotidine" by people in this website by year, and whether "Famotidine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 3 | 0 | 3 |
| 2008 | 1 | 1 | 2 |
| 2010 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Famotidine" by people in Profiles.
-
No evidence of clinical efficacy of famotidine for the treatment of COVID-19: a systematic review and meta-analysis. J Infect. 2023 02; 86(2):154-225.
-
Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Support Care Cancer. 2015 Jul; 23(7):2019-24.
-
Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma. Cancer Biother Radiopharm. 2010 Apr; 25(2):179-83.
-
High-dose intensity pulse interleukin-2 with famotidine has activity in metastatic melanoma. Cancer Biother Radiopharm. 2008 Oct; 23(5):641-6.
-
Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer. Cancer Biother Radiopharm. 2008 Feb; 23(1):108-13.
-
Continuous infusion interleukin-2 and intravenous famotidine in metastatic melanoma. Cancer Biother Radiopharm. 2006 Dec; 21(6):607-12.
-
Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2. Cancer Biother Radiopharm. 2006 Oct; 21(5):437-42.
-
Continuous infusion interleukin-2 and famotidine in metastatic kidney cancer. Cancer Biother Radiopharm. 2006 Oct; 21(5):515-9.
-
Pharmacokinetics of famotidine in infants. Clin Pharmacokinet. 2005; 44(4):395-406.
-
False negative urea breath tests with H2-receptor antagonists: interactions between Helicobacter pylori density and pH. Helicobacter. 2004 Feb; 9(1):17-27.